에서 실시간으로 운영 중이에요! 자세히 알아보기
ATNX

Athenex, Inc. Common Stock

상장 폐지됨

ATNX은(는) 2023년 5월 24일에 상장 폐지됐어요.

 

소개: Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

직원 수: 280

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 0%
중립 0%
부정적 0%

ATNX에 대한 최신 뉴스 기사를 아직 받지 못했어요.

Lightweight Charts™를 사용해 가격 차트를 구현했어요.